Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.95 -3.9%	$1.51	$0.66 ▼ $3.00	$188.80M	2.55	1.94 million shs	1.25 million shs
CTMX CytomX Therapeutics	$2.35 +7.3%	$2.41	$0.40 ▼ $3.10	$176.56M	2.13	1.41 million shs	1.45 million shs
JSPR Jasper Therapeutics	$2.88 -0.7%	$4.68	$2.27 ▼ $26.05	$43.56M	2.69	1.36 million shs	268,314 shs
TLSA Tiziana Life Sciences	$2.38 -4.8%	$1.60	$0.63 ▼ $2.60	$292.12M	-0.58	339,794 shs	863,995 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	-3.94%	-14.47%	+42.34%	+121.59%	-15.95%
CTMX CytomX Therapeutics	+7.31%	-2.08%	-5.24%	+193.02%	+70.29%
JSPR Jasper Therapeutics	-0.69%	-8.57%	-57.77%	-46.77%	-84.42%
TLSA Tiziana Life Sciences	-4.80%	+27.96%	+51.59%	+85.94%	+122.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.4368 of 5 stars	3.5	4.0	0.0	0.6	1.7	0.6
CTMX CytomX Therapeutics	4.0091 of 5 stars	3.5	1.0	4.7	1.9	1.7	1.3
JSPR Jasper Therapeutics	2.7047 of 5 stars	4.3	2.0	0.0	1.1	1.7	0.6
TLSA Tiziana Life Sciences	0.8919 of 5 stars	0.0	3.0	0.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$8.50	335.90% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	144.68% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	932.99% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest JSPR, CRBU, CTMX, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.99M	18.15	N/A	N/A	$2.79 per share	0.70
CTMX CytomX Therapeutics	$138.10M	1.37	$0.39 per share	6.05	($0.01) per share	-235.00
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	4.90	N/A	N/A	28.22%	-553.71%	32.21%	8/7/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest JSPR, CRBU, CTMX, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	CTMX CytomX Therapeutics	-$0.05	N/A	N/A	N/A	$19.10 million	N/A
8/5/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.63	7.63
CTMX CytomX Therapeutics	N/A	1.73	1.73
JSPR Jasper Therapeutics	N/A	4.31	4.31
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
CTMX CytomX Therapeutics	67.77%
JSPR Jasper Therapeutics	79.85%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
CTMX CytomX Therapeutics	6.60%
JSPR Jasper Therapeutics	4.60%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.00 million	85.30 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

JSPR, CRBU, CTMX, and TLSA Headlines

Recent News About These Companies

Dauntless Investment Group LLC Buys Shares of 1,739,574 Tiziana Life Sciences Ltd (NASDAQ:TLSA)

July 29, 2025 | marketbeat.com

Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

July 21, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21, 2025 | globenewswire.com

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 2.6% - Here's Why

July 9, 2025 | marketbeat.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.comP

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, CRBU, CTMX, and TLSA Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.95 -0.08 (-3.94%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.94 0.00 (-0.26%)

As of 08/1/2025 07:55 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

CytomX Therapeutics NASDAQ:CTMX

$2.35 +0.16 (+7.31%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.40 +0.04 (+1.91%)

As of 08/1/2025 07:41 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Jasper Therapeutics NASDAQ:JSPR

$2.88 -0.02 (-0.69%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.85 -0.03 (-1.01%)

As of 08/1/2025 07:50 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Tiziana Life Sciences NASDAQ:TLSA

$2.38 -0.12 (-4.80%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.41 +0.03 (+1.43%)

As of 08/1/2025 07:58 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time